Market Overview

UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products

Related BLUE
These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold
Bluebird Bio Initiated Hold At Cantor Fitzgerald, Decides To Await Additional Data
The Vetr community has downgraded $BLUE to 4-Stars (Vetr)

In a report published on Monday, J.P. Morgan analyst Cory Kasimov initiated coverage on bluebird bio (NASDAQ: BLUE) with an Overweight rating and a $44 price target.

In the report, J.P. Morgan stated, "Catchy titles aside, bluebird bio is anything but “Old School.” Quite the contrary. In our view, BLUE – with its gene therapy platform – is one of the more potentially transformative and disruptive companies we've come across in some time. Importantly, however, this appears to be more than just a “big idea.” bluebird has already established promising proof-of-concept for its two lead products and is going after orphan indications with a very high unmet medical need that could bolster the ultimate probability of success."

bluebird bio closed on Friday at $30.65.

Latest Ratings for BLUE

Jun 2016Cantor FitzgeraldInitiates Coverage onHold
Mar 2016BTIG ResearchInitiates Coverage onBuy
Feb 2016Leerink SwannInitiates Coverage onOutperform

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Cory Kasimov J.P.MorganAnalyst Color Initiation Analyst Ratings


Related Articles (BLUE)

View Comments and Join the Discussion!